Tirzepatide dosing charts on TikTok: what they get wrong

What's this video probably claiming?

A "helpful dosing chart" for tirzepatide almost certainly lays out a week-by-week escalation schedule, likely starting at 2.5 mg weekly and climbing toward 5, 7.5, 10, 12.5, or 15 mg. Creators in this space typically present these charts as a kind of cheat sheet, implying that users can self-direct their dose timing, decide when to "jump" to the next tier based on weight loss pace, or compare their progress against some community benchmark. Some versions circulating on TikTok also conflate the FDA-approved Zepbound titration schedule with compounded tirzepatide protocols, which are not the same thing legally or clinically. The chart format gives the impression of clinical authority it does not actually have.

Given the hashtag category and creator handle with no verified medical credentials visible, this is almost certainly a lay person sharing a protocol they followed personally, a screenshot from a Reddit thread, or a repackaged version of the Eli Lilly prescribing information stripped of all the clinical caveats that make it meaningful.

What does the science actually show?

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) established the tirzepatide dose escalation schedule used in clinical practice: patients started at 2.5 mg once weekly and increased by 2.5 mg every four weeks, targeting a maintenance dose of 5, 10, or 15 mg. At the 15 mg dose, participants lost a mean of 20.9% of body weight over 72 weeks. That is genuinely impressive data. But the titration schedule was not arbitrary. It was designed specifically to minimize GI adverse events, which still affected roughly 40% of participants at higher doses even with slow escalation.

What the trial did not do is validate faster escalation, dose skipping, or patient-directed timing adjustments. The four-week intervals between dose increases exist because gastric emptying changes, nausea peaks, and individual GLP-1 receptor sensitivity varies considerably. There is no published evidence that accelerating that schedule improves outcomes, and reasonable mechanistic grounds to expect it worsens tolerability.

Where does the social media noise diverge from clinical reality?

The biggest problem with DIY dosing charts is the implied permission structure. Seeing a chart formatted like a medical table makes people feel like they have clinical backing for self-escalating. They do not. Tirzepatide is a Schedule III-adjacent controlled substance in several states and a prescription drug everywhere in the US. The prescribing information from Eli Lilly explicitly states that dose escalation decisions should be individualized by a provider based on tolerability, not a fixed community timeline.

A second major divergence: many TikTok charts circulating right now are based on compounded tirzepatide concentrations, which differ from Zepbound in ways that matter. The FDA has stated that compounded tirzepatide is not FDA-approved and cannot be considered equivalent to Zepbound. Mixing up the two when building a dosing chart is not a minor editorial error. It is clinically meaningful misinformation, because concentration, excipient composition, and reconstitution instructions all affect delivered dose.

What should you actually know?

Tirzepatide's dual GIP and GLP-1 receptor agonism is what separates it mechanistically from semaglutide, and the clinical weight loss data is stronger. The SURMOUNT program across multiple trials shows consistent 15-22% body weight reduction at maximum doses. But those results came from people under medical supervision with standardized titration, not from following a chart someone made in Canva.

• The FDA-approved starting dose is 2.5 mg weekly for four weeks before any increase.
• GI side effects are the primary reason titration is slow. Rushing it does not accelerate fat loss. It accelerates nausea.
• Compounded tirzepatide is not FDA-approved and has different regulatory standing than Zepbound or Mounjaro.
• Individual dose ceilings depend on tolerability, not on what week a chart says you should be at.
• Any dosing decision should involve a licensed prescriber who knows your full medical history.